In a report released yesterday, Maxwell Skor from Morgan Stanley maintained a Buy rating on TScan Therapeutics (TCRX – Research Report), with a price target of $10.00.
Maxwell Skor has given his Buy rating due to a combination of factors that highlight the potential of TScan Therapeutics. The company’s focus on developing T cell receptor-engineered therapies for both liquid and solid tumors is a promising approach in the field of cancer treatment. Their proprietary TargetScan platform aims to identify specific TCR/target pairs that could drive clinical responses, which is a significant advancement in leveraging immunotherapy for a broader range of cancer patients.
Additionally, the recent data from the PhI ALLOHA trial is encouraging, particularly the lower relapse rate observed in the TSC treatment arm compared to the control group. This suggests a favorable event-free survival rate, which is a positive indicator for the ongoing development of their therapies. With pivotal studies and updates on multiplex TCR-T therapy expected in the near future, Skor sees potential growth and success for TScan Therapeutics, justifying the Buy rating.
Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TCRX in relation to earlier this year.